Evidence map›Paper›PMID 42193291›Full record

ReviewBiomedicines2026

Immunomodulatory Nanomaterials: Design Strategies, Mechanisms, Biomedical Applications, and Future Perspectives.

Maharshi Thalla, Sumedha Kapre, Sushesh Srivatsa Palakurthi, Praveen Kolimi, Ravi Akkireddy, Geetha Satya Sainaga Jyothi Vaskuri, Nagavendra Kommineni, Rahul Sharma, Jae D Kim, Srinath Palakurthi

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biomedicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Maharshi ThallaDepartment of Pharmaceutical Sciences, Irma Lerma Rangel College of Pharmacy, Texas A&M University, Kingsville, TX 78363, USA.ORCID 0000-0002-9545-6929
Sumedha KapreDepartment of Pharmaceutical Sciences, Irma Lerma Rangel College of Pharmacy, Texas A&M University, Kingsville, TX 78363, USA.
Sushesh Srivatsa PalakurthiDepartment of Pharmaceutical Sciences, Irma Lerma Rangel College of Pharmacy, Texas A&M University, Kingsville, TX 78363, USA.
Praveen KolimiDepartment of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, Oxford, MS 38677, USA.
Ravi AkkireddyCancer Center, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.ORCID 0009-0009-5843-8287
Geetha Satya Sainaga Jyothi VaskuriDepartment of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN 38163, USA.ORCID 0000-0002-0479-6873
Nagavendra KommineniThermo Fischer Scientific Inc., Cincinnati, OH 45237, USA.ORCID 0000-0003-4771-7925
Rahul SharmaDivision of Nephrology, Department of Medicine, University of Virginia, P.O. Box 800133, Charlottesville, VA 22903, USA.ORCID 0000-0002-3115-3523
Jae D KimCorpus Christi Gastroenterology PLLC (Professional Limited Liability Company), Saratoga Boulevard Building, Corpus Christi, TX 78414, USA.
Srinath PalakurthiDepartment of Pharmaceutical Sciences, Irma Lerma Rangel College of Pharmacy, Texas A&M University, Kingsville, TX 78363, USA.ORCID 0000-0002-9509-9511

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The utilization of immunomodulatory nanomaterials, i.e., leveraging their unique properties to enhance immune responses, represents a transformative approach for the treatment of various diseases. Recent advancements in nanotechnology have enabled the design of nanomaterials capable of delivering immunomodulatory agents in a targeted manner, such as cytokines, antibodies, and nucleic acids, to specific cells or tissues involved in immune regulation. These nanomaterials, including nanoparticles, liposomes, nanogels, nanoemulsions, dendrimers, MXenes and extracellular vesicles, have been increasingly tailored to modulate immune responses with precision and efficacy. This targeted approach not only enhances therapeutic outcomes but also reduces off-target effects, minimizing systemic toxicity. In this review, an overview of immunomodulatory nanomaterials and their biomedical applications are highlighted. Herein, we have discussed different types of nanomaterials and their design strategies, interactions with different immune system components (macrophages, dendritic cells (DCs), neutrophils, T lymphocytes (CD4

Indexed as

disease treatmentimmune regulationimmunomodulationnanomaterialswound healing and bone regeneration

Identifiers

PMID42193291
PMCPMC13203554

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.